1-(4-Bromophenyl)-2,5-Dimethylpyrrole

When a Suzuki Coupling Partner Meets Multi-Kilogram cGMP Requirements

In the context of a late-stage functionalisation programme for a clinical orexin receptor antagonist, 1-(4-bromophenyl)-2,5-dimethylpyrrole serves as a critical aryl bromide building block in a palladium-catalysed Suzuki-Miyaura cross‑coupling with a boronic acid pinacol ester derived from a tetrahydroisoquinoline fragment. The aryl bromide is charged at a molar ratio of 1.00–1.05 relative to the boronic acid partner; exceeding 1.05 equivalents triggers a detectable rise in the diarylated homocoupling by‑product to 0.15–0.20 area% by HPLC, which cannot be efficiently purged by simple crystallisation and demands preparative chromatography that is commercially prohibitive beyond pilot scale. The downstream manufacturing process is executed in a 500‑L glass‑lined Hastelloy C‑22 reactor under a nitrogen atmosphere with a toluene/ethanol/water mixture (3:1:1 v/v), containing potassium carbonate at 2.5 molar equivalents. After sparging the biphasic system with nitrogen for 30 minutes, palladium(II) acetate (0.5 mol%) and triphenylphosphine (1.5 mol%) are introduced, and the jacket temperature is ramped to achieve a gentle reflux at 78±2 °C. The reaction progression is monitored by in‑process HPLC with UV detection at 254 nm; typical conversion reaches 98.5% within 8–12 hours. Post‑reaction phase separation is followed by a scavenging step wherein the organic layer is stirred with a thiol‑functionalised silica adsorbent (SiliaMetS® Thiol) for 4 hours at 50 °C, reducing residual palladium to below 5 µg/g as measured by USP 〈233〉 ICP‑MS. The crude biaryl intermediate is then concentrated and crystallised from isopropanol/water (2:1 v/v), affording an off‑white crystalline solid with a purity exceeding 99.5 area% and single unknown impurity below 0.10 area%, fully compliant with ICH Q7 Section 7.3 process validation requirements and ICH Q3D elemental impurity limits for an oral drug substance (palladium oral permitted daily exposure = 10 µg/day). The resulting biaryl intermediate becomes the cornerstone of a Phase II investigation new drug candidate targeting dual orexin receptors for the treatment of insomnia, with the entire synthesis route designed to avoid genotoxic impurities and chlorinated solvents, thereby aligning with the EMA Guideline on the Limits of Genotoxic Impurities and ICH Q3C residual solvent classes. Compliance is further anchored to 21 CFR Part 210/211 for finished pharmaceutical dosage forms, although the intermediate itself falls under active pharmaceutical ingredient starting material controls where a valid Drug Master File is maintained.

What Drives Hole Mobility in n‑i‑p Perovskite Architectures?

The n‑i‑p perovskite device stack, commonly configured as FTO/compact‑TiO₂/perovskite/hole‑transporting‑layer/Au, imposes stringent demands on the hole‑transporting material (HTM): deepest HOMO level alignment, high hole mobility, and robust film morphology under thermal stress. 1‑(4‑Bromophenyl)-2,5‑dimethylpyrrole is employed not as a discrete small‑molecule HTM but as a dibromo‑aryl co‑monomer in a Suzuki polycondensation with 9,9‑dioctylfluorene‑2,7‑diboronic acid pinacol ester to generate a donor‑acceptor‑type polymer wherein the dimethylpyrrole unit raises the HOMO level towards −5.15 eV and enhances face‑on π‑stacking. The feed ratio of the bromopyrrole monomer is controlled within 35–50 mol% of total aromatic dibromides; at additions below 30 mol% the hole mobility measured by the space‑charge‑limited‑current (SCLC) method according to J. Appl. Phys. 83, 7949 (1998) collapses below 10⁻⁵ cm²/V·s, whereas above 55 mol% the polymer becomes excessively rigid, causing film roughening and pinholes that drop the shunt resistance below 1 kΩ·cm² in finished devices. The downstream polymerisation is conducted in a 20‑L glass‑lined reactor containing anhydrous toluene, aqueous potassium carbonate (4 M, 3 equivalents), and tetrakis(triphenylphosphine)palladium(0) (2 mol%) under a continuous argon blanket. The mixture is heated at 95 °C for 48 hours with overhead stirring at 250 rpm; end‑capping with bromobenzene for 6 hours is applied to eliminate residual boronic ester end‑groups that would otherwise accelerate photochemical degradation. Crude polymer is precipitated in methanol, filtered, and purified by sequential Soxhlet extraction with acetone (24 h), hexane (12 h), and toluene (12 h) until the residual palladium content drops below 50 ppb as determined by inductively coupled plasma optical emission spectrometry. The purified polymer is dissolved in chlorobenzene at 10 mg/mL and blade‑coated in a Class‑100 cleanroom onto the perovskite sub‑layer, yielding a dry film thickness of 120 ± 10 nm. Finished modules are subjected to the damp heat test of IEC 61215‑2:2021 (85 °C, 85% relative humidity, 1000 hours), requiring power output degradation below 5% relative to initial STC measurement, and additional UV preconditioning per ISO 4892‑2 cycle 1 is executed to verify packaging robustness. The terminal product is a flexible perovskite photovoltaic module for building‑integrated photovoltaics, with an aperture power conversion efficiency exceeding 18% on a 30 cm × 30 cm monolithic serial interconnection and an expected outdoor service life validated beyond 2000 hours in IEC 61215 sequential testing.

The organomagnesium route from 1‑(4‑bromophenyl)‑2,5‑dimethylpyrrole to β‑substituted tertiary alcohols has been integrated into a continuous‑flow kilo‑lab campaign at a contract manufacturing organisation specifically to circumvent the inherent scale‑up risks of a batch Grignard initiation—particularly the well‑documented induction period that can trigger a sudden exotherm once autocatalytic surface activation of magnesium occurs. An anhydrous tetrahydrofuran solution of the aryl bromide (0.5 M) is pumped through a column packed with Rieke‑type magnesium turnings (pretreated with 0.5 vol% 1,2‑dibromoethane as an entrainment initiator) maintained at 40 °C with a residence time of 120 seconds inside a Corning Advanced‑Flow G1 glass reactor module (channel hydraulic diameter 0.5 mm, heat exchange fluid at −15 °C). Microcalorimetric evaluation of the neat Grignard formation via adiabatic reaction calorimetry (Phi‑TEC II) revealed an adiabatic temperature rise (ΔT_ad) exceeding 180 °C and a maximum achievable temperature of synthesis (MTSR) of 85 °C under loss‑of‑cooling conditions, which prompted the shift to flow with an extremely high surface‑to‑volume ratio that removes heat faster than the 120‑second reaction window. The freshly generated Grignard stream is immediately combined with a pre‑cooled cyclobutanone solution (1.05:1 molar ratio of ketone to Grignard in tetrahydrofuran) at −5 °C in a second Corning G1 reactor module; the inverse addition strategy suppresses the Wurtz‑type homocoupling dimer that otherwise forms at 3–5% when the Grignard is in excess relative to the electrophile. In‑line quenching with 20 wt% aqueous ammonium chloride is performed in a third reactor module, followed by phase separation through a Zaiput membrane separator (PTFE membrane, 1.0 µm pore size). The organic stream is collected continuously, dried over molecular sieves, and distilled under reduced pressure (0.5 mbar, pot temperature 95 °C) in a wiped‑film evaporator to yield the tertiary alcohol with a purity exceeding 99.0 area% by GC and an APHA colour value below 50 per ASTM E308‑18. Compliance for process safety documentation aligns with the DIERS two‑phase flow methodology of ISO 4126‑10, which governs emergency relief system sizing for the Grignard reactor, while quality release is performed against a monograph that includes the limit test for total peroxides (<0.1 mmol/kg) to prevent runaway decomposition of residual tetrahydrofuran peroxides during distillation. The tertiary alcohol intermediate is subsequently elaborated into a histamine H3 receptor antagonist commercialised for narcolepsy; the entire campaign routinely supplies 25–50 kg per batch under a quality agreement that mirrors ICH Q7 for active pharmaceutical ingredient starting materials with extended stability monitoring per WHO Technical Report Series 953 Annex 2.

Pyrrole‑Based Monomer Feedstock for High‑RI Optical Polymer Films

For augmented‑reality waveguide combiners requiring a refractive index above 1.60 at 589 nm and high Abbe number to minimise chromatic dispersion, brominated aryl‑pyrrole monomers are first derivatised to allyl‑functionalised co‑monomers via a palladium‑catalysed Heck reaction of 1‑(4‑bromophenyl)‑2,5‑dimethylpyrrole with allyl alcohol, and subsequently incorporated into thiol‑ene networks to raise the molar refraction density. The allylation is performed in a 50‑L glass‑lined reactor using palladium(II) acetate (0.3 mol%), tributylphosphine (0.9 mol%), and sodium carbonate (2 equivalents) in N,N‑dimethylformamide at 110 °C for 14 hours, affording the 4‑(prop‑2‑en‑1‑yl)phenyl‑2,5‑dimethylpyrrole intermediate after distillation at 0.2 mbar. In the final optical formulation, this allyl‑functionalised monomer is combined with pentaerythritol tetrakis(3‑mercaptopropionate) at a weight ratio corresponding to 20–40 wt% of the pyrrole component in the total monomer feed; at 25 wt% loading the UV‑cured film reaches a refractive index of 1.632 (589 nm, Abbé refractometer per ASTM D542‑22) and a through‑plane birefringence below 0.002. The liquid resin, containing Irgacure 184 photoinitiator at 0.5 wt%, is slot‑die coated onto a primed polyethylene terephthalate carrier film in a nitrogen‑purged tunnel oven (residual oxygen <100 ppm) and cured by exposure to a 365 nm LED array at an irradiance of 2 J/cm². Post‑cure annealing at 80 °C for 2 hours eliminates residual thiol odour and raises the glass transition temperature to 68 °C as measured by differential scanning calorimetry. Because the bromine atom is fully substituted during the Heck allylation, the final optical film contains no detectable free brominated species, ensuring compliance with the declaration requirements of IEC 62474 for materials in electronic products and obviating the need for a restriction dossier under REACH Annex XVII Entry 63 (which applies only to certain brominated flame retardants). Optical transmission is characterised by ISO 13468‑1:2019, with film specimens demonstrating a total luminous transmittance exceeding 92% and a haze value below 0.5%. The finished thin‑film waveguide is integrated into an augmented‑reality headset combiner, enabling full‑colour field uniformity across a 40° field of view, and environmental stability testing is conducted under 85 °C/85% RH for 500 hours with a shift in refractive index of less than ±0.002.

A telescoped lithiation‑formylation‑condensation sequence converting 1‑(4‑bromophenyl)‑2,5‑dimethylpyrrole into a cyanoacrylamide SDHI fungicide intermediate has been qualified on a 1000‑L scale at a multipurpose agrochemical facility. The key step exploits the aromatic bromide as a directing handle for a halogen–lithium exchange: a pre‑cooled tetrahydrofuran solution of the bromo‑arene is treated with n‑butyllithium (1.03 equivalents, 2.5 M in hexanes) at −78 °C under an argon atmosphere, and the resulting aryl lithium species is quenched with dimethylformamide (1.3 equivalents) to install a formyl group at the position formerly occupied by bromine. The exothermicity of the lithium–halogen exchange demands strict temperature control; plant‑scale risk assessment according to the Stoessel cooling-failure scenario indicated that the accumulation of unreacted n‑butyllithium above 5% of the charged amount would generate a secondary decomposition event above −30 °C, so the addition is paced by a mass flow meter to maintain internal temperature below −72 °C and the reaction is immediately quenched with dimethylformamide once a residual aryl bromide level below 1% is confirmed by in‑line Raman spectroscopy (peak at 1050 cm⁻¹ for C–Br stretch). After aqueous workup and removal of the lithium salt, the crude aldehyde intermediate is telescoped directly into a Knoevenagel condensation with cyanoacetamide at a 1:1.2 molar ratio in ethanol containing piperidine (5 mol%) at reflux for 6 hours. The (E)‑cyanoacrylamide product precipitates upon cooling and is recrystallised from toluene/cyclohexane (1:3 v/v), affording a pale‑yellow crystalline solid with a purity exceeding 99.5% by HPLC (UV 310 nm) and a melting point of 168–170 °C. During early kilo‑lab runs, a batch failure was traced to residual tetrahydrofuran peroxides present in recovered solvent; this instigated a mandatory incoming‑solvent specification that requires butylated hydroxytoluene (BHT) stabiliser content above 250 ppm and Karl Fischer water below 50 ppm before the lithium–halogen exchange step. The cyanoacrylamide intermediate is a critical precursor for an experimental succinate dehydrogenase inhibitor (SDHI) fungicide currently undergoing field trial evaluation for the control of cereal rusts in EU zones where triazole chemistries face phase‑out due to endocrine‑disrupting concerns. All analytical release data are generated according to CIPAC Method MT 46.3 for wet sieve analysis and OECD Guideline 509 for storage stability at 54 °C for 14 days, which demonstrates less than 2% degradation of the active intermediate. The formulation development laboratory uses this intermediate to synthesise kilogram batches of the final emusifiable concentrate (EC) formulation for field efficacy screening, requiring a shelf‑life specification of 2 years at ambient storage per CIPAC MT 39.3.